Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article “ LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma “ in Communications Biology.